Edition:
India

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

59.55EUR
19 Jul 2019
Change (% chg)

€0.79 (+1.34%)
Prev Close
€58.76
Open
€59.59
Day's High
€60.03
Day's Low
€59.03
Volume
3,075,454
Avg. Vol
3,637,683
52-wk High
€97.03
52-wk Low
€52.02

Latest Key Developments (Source: Significant Developments)

Bayer Starts Phase III Trial Of Aflibercept
Friday, 21 Jun 2019 

June 21 (Reuters) - BAYER AG ::HAS INITIATED A PHASE III TRIAL OF ITS ANTI-VEGF TREATMENT AFLIBERCEPT FOR INTRAVITREAL INJECTION IN RETINOPATHY OF PREMATURITY (ROP).APPROXIMATELY 100 INFANTS WILL BE ENROLLED IN 34 COUNTRIES.RETINOPATHY OF PREMATURITY IS EYE CONDITION IN PREMATURE INFANTS WHICH CAN LEAD TO IRREVERSIBLE BLINDNESS.  Full Article

Arvinas Says Under Terms Of Bayer Agreement, Co Will Receive Upfront Payment Of $17.5 Mln Within 30 Days Of The Effective Date
Tuesday, 4 Jun 2019 

June 4 (Reuters) - Arvinas Inc ::ARVINAS INC - UNDER TERMS OF BAYER COLLABORATION AGREEMENT, CO WILL RECEIVE UPFRONT PAYMENT OF $17.5 MILLION WITHIN 30 DAYS OF THE EFFECTIVE DATE..ARVINAS INC - ALSO ENTITLED TO RECEIVE UP TO AN ADDITIONAL $12.0 MILLION IN RESEARCH FUNDING PAYMENTS.ARVINAS-ELIGIBLE TO RECEIVE, ON NET SALES OF PROTAC TARGETED PROTEIN DEGRADER-RELATED PRODUCTS, MID-SINGLE DIGIT TO LOW-DOUBLE DIGIT TIERED ROYALTIES.ARVINAS-ALSO ELIGIBLE TO RECEIVE UP TO $197.5 MILLION IN DEVELOPMENT MILESTONES AND UP TO $490.0 MILLION IN SALES-BASED MILESTONES FOR ALL DESIGNATED TARGETS..  Full Article

Bayer And Arvinas To Develop Novel Proteolysis-Targeting Chimera Candidates For Humans And Plants
Tuesday, 4 Jun 2019 

June 4 (Reuters) - BAYER AG ::BAYER AND ARVINAS, INC. TO DEVELOP NOVEL PROTEOLYSIS-TARGETING CHIMERA CANDIDATES FOR HUMANS AND PLANTS.AGREEMENT WORTH MORE THAN USD 110 MILLION.BAYER AND ARVINAS TO LAUNCH JOINT VENTURE TO DEVELOP TARGETED PROTEIN DEGRADERS FOR AGRICULTURE APPLICATIONS.COLLABORATION AGREEMENT AND EQUITY INVESTMENT BY BAYER TO DEVELOP NEXT-GENERATION MEDICINES FOR PATIENTS WITH CARDIOVASCULAR, ONCOLOGICAL AND GYNECOLOGICAL DISEASES.UNDER TERMS OF AGREEMENT, ARVINAS WILL RECEIVE AN UPFRONT PAYMENT AND PHARMACEUTICAL R&D SUPPORT OVER NEXT FOUR YEARS, AS WELL AS A DIRECT EQUITY INVESTMENT.THESE INVESTMENTS COMBINED WILL EXCEED USD 60 MLN.ARVINAS MIGHT ALSO BE ELIGIBLE TO RECEIVE PRE-DEFINED DEVELOPMENT MILESTONES OF OVER USD 685 MLN AND COMMERCIAL ROYALTIES.  Full Article

Bayer And Arvinas To Collaborate On Human Protac Therapies And Launch A Separate Joint Venture To Develop Agricultural Protac Applications
Tuesday, 4 Jun 2019 

June 4 (Reuters) - Arvinas Inc ::BAYER AND ARVINAS TO COLLABORATE ON HUMAN PROTAC® THERAPIES AND LAUNCH A SEPARATE JOINT VENTURE TO DEVELOP AGRICULTURAL PROTAC® APPLICATIONS.ARVINAS INC - BAYER AND ARVINAS TO LAUNCH A JOINT VENTURE TO DEVELOP TARGETED PROTEIN DEGRADERS FOR AGRICULTURAL APPLICATIONS.ARVINAS INC - $110M+ LIFE SCIENCES DEAL TO DEVELOP NOVEL PROTAC® CANDIDATES.ARVINAS INC - OVERALL SERIES OF ARRANGEMENTS INCLUDES OVER $110 MILLION IN UPFRONT CASH AND COMMITTED FUNDING FOR HUMAN DISEASE COLLABORATION.ARVINAS INC - CLOSING OF THE MULTI-FACETED DEAL WITH BAYER, OTHERS WILL LEAD TO UPDATED FINANCIAL GUIDANCE FOR ARVINAS.ARVINAS INC - BAYER WILL OWN RIGHTS TO NOVEL LEAD STRUCTURES GENERATED IN COLLABORATION.ARVINAS - ALSO ELIGIBLE TO GET DEVELOPMENT MILESTONES OF OVER $685 MILLION & COMMERCIAL ROYALTIES RANGING FROM MID-SINGLE DIGITS TO LOW DOUBLE-DIGITS.ARVINAS INC - ARVINAS WILL RECEIVE AN UPFRONT PAYMENT AND COMMITTED RESEARCH AND DEVELOPMENT FUNDING, AS WELL AS A DIRECT EQUITY INVESTMENT IN ARVINAS.ARVINAS INC - BAYER AND ARVINAS WILL EQUALLY SHARE GOVERNANCE AND EQUITY OWNERSHIP OF JV.ARVINAS - THE JV WILL BE SUPPORTED BY IP & OVER $55 MILLION IN COMMITTED FUNDING FROM BAYER, AND BY TECHNOLOGY AND INTELLECTUAL PROPERTY FROM ARVINAS.  Full Article

Bayer, Foundation Medicine Announce Global Collaboration To Develop Next-Generation Sequencing-Based Companion Diagnostics
Wednesday, 29 May 2019 

May 29 (Reuters) - Bayer AG ::BAYER & FOUNDATION MEDICINE ANNOUNCE GLOBAL COLLABORATION TO DEVELOP NEXT-GENERATION SEQUENCING (NGS)-BASED COMPANION DIAGNOSTICS IN ONCOLOGY.BAYER - COLLABORATION WILL START WITH DEVELOPMENT OF A COMPANION DIAGNOSTIC FOR VITRAKVI.BAYER - FINANCIAL TERMS OF AGREEMENT WERE NOT DISCLOSED.  Full Article

Bayer Receives U.S. FDA Breakthrough Therapy Designation For Aliqopa
Wednesday, 29 May 2019 

May 29 (Reuters) - Bayer AG ::BAYER RECEIVES U.S. FDA BREAKTHROUGH THERAPY DESIGNATION FOR ALIQOPA™ (COPANLISIB) FOR THE TREATMENT OF MARGINAL ZONE LYMPHOMA.BAYER-CONDUCTING 2 ADDITIONAL PHASE III STUDIES-CHRONOS-3, CHRONOS-4-TO CONFIRM EFFICACY AND SAFETY OF ALIQOPA IN COMBINATION WITH OTHER THERAPIES IN INHL.  Full Article

FDA Received About 6,000 Medical Device Reports In 2018 Related To Bayer's Essure Device
Thursday, 16 May 2019 

May 15 (Reuters) - U.S. Food and Drug Administration::U.S. FDA SAYS UPDATED ITS ESSURE WEBSITE TO INCLUDE AN ANALYSIS OF MEDICAL DEVICE REPORTS RECEIVED IN 2018.U.S. FDA - RECEIVED ABOUT 6,000 MEDICAL DEVICE REPORTS IN 2018 RELATED TO ESSURE, DOWN FROM THE NEARLY 12,000 MEDICAL DEVICE REPORTS RECEIVED IN 2017.U.S. FDA - MOST OF THE REPORTS RELATED TO ESSURE RECEIVED BY FDA IN 2018 WERE SUBMITTED BY BAYER AND ARE RELATED TO LITIGATION AGAINST THE COMPANY.U.S. FDA - MOST OF THE REPORTS RELATED TO ESSURE RECEIVED BY FDA IN 2018 MENTION POTENTIAL DEVICE REMOVAL.U.S. FDA - AS OF APRIL 1, 891 PATIENTS HAVE BEEN ENROLLED IN THE POSTMARKET SURVEILLANCE STUDY ON ESSURE THAT FDA ORDERED BAYER TO CONDUCT IN 2016.  Full Article

Bayer: US FDA Accepts New Drug Application And Grants Priority Review For Darolutamide
Monday, 29 Apr 2019 

April 29 (Reuters) - BAYER AG ::U.S. FDA ACCEPTS NEW DRUG APPLICATION AND GRANTS PRIORITY REVIEW FOR DAROLUTAMIDE.DAROLUTAMIDE FOR TREATMENT OF NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC).  Full Article

Bayer Proposes Dividend For 2018 Of 2.80 Euros Per Share
Tuesday, 26 Feb 2019 

Feb 26 (Reuters) - Bayer AG ::BAYER NEWS RELEASE: BAYER PROPOSES DIVIDEND FOR 2018 OF 2.80 EUROS PER SHARE.TOTAL DIVIDEND PAYMENT WOULD AMOUNT TO 2.611 BILLION EUROS (2017: 2.402 BILLION EUROS), REPRESENTING AN INCREASE OF 8.7 PERCENT.  Full Article

Moberg Pharma Reports Qtrly Diluted Earnings Per Share SEK 0.62
Tuesday, 12 Feb 2019 

Feb 11 (Reuters) - Moberg Pharma Ab (Publ) ::MOBERG PHARMA AB YEAR-END REPORT 2018.SAYS FULL YEAR 2018 NET REVENUE SEK 439.0 MILLION.QTRLY DILUTED EARNINGS PER SHARE SEK 0.62.SAYS BOARD OF DIRECTORS PROPOSES THAT NO DIVIDEND BE PAID FOR 2018.MOBERG PHARMA AB - QTRLY NET REVENUE SEK 97.1 MILLION.Q4 REVENUE VIEW SEK 90.0 MILLION -- REFINITIV IBES DATA.Q4 EARNINGS PER SHARE VIEW SEK 0.45 -- REFINITIV IBES DATA.FY2018 REVENUE VIEW SEK 432.0 MILLION -- REFINITIV IBES DATA.FY2018 EARNINGS PER SHARE VIEW SEK 0.96 -- REFINITIV IBES DATA.SAYS SIGNED A LICENSE AGREEMENT WITH BAYER AG TO COMMERCIALIZE MOB-015 IN EUROPE.QTRLY U.S. SALES WERE STRONG , CONTRIBUTING TO DOUBLE-DIGIT GROWTH FOR FULL YEAR.SAYS MOBERG PHARMA IS ELIGIBLE TO RECEIVE MILESTONES PAYMENTS UP TO EUR 50 MILLION FROM AGREEMENT WITH BAYER AG.Q4 NET REVENUE SEK 97.1 MILLION.SAYS Q4 OPERATING CASH FLOW PER SHARE SEK 0.95 (1.68).SAYS FULL YEAR 2018 DILUTED EARNINGS PER SHARE SEK 1.14 (0.64).MOBERG - IN BEGINNING OF 2019, SCREENING OF PATIENTS TO EUROPEAN PHASE 3 STUDY FOR MOB-015 FINALIZED ;EXPECT RANDOMIZATION TO BE COMPLETED DURING Q1.MOBERG PHARMA-CAN EXPECT TOPLINE RESULTS FOR MOB-015 U.S. PHASE 3 STUDY IN LATE 2019,CORRESPONDING RESULTS FROM EUROPEAN PHASE 3 STUDY IN Q2 OF 2020.  Full Article

Syngenta CFO says it faces no glyphosate lawsuits

ZURICH, July 19 Chinese-owned agricultural chemical maker Syngenta has not been named in litigation involving weed-killer ingredient glyphosate that has hit German rival Bayer, the Swiss-based company's chief financial officer, Mark Patrick, said on Friday.